EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

by Riley Nolan | Jun 22, 2021

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

by Riley Nolan | Mar 23, 2021

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes
Identification of a potent regulatory T cell epitope infactor V that modulates CD4+ and CD8+ memory T cell responses

Identification of a potent regulatory T cell epitope infactor V that modulates CD4+ and CD8+ memory T cell responses

by Annie De Groot | Jan 13, 2021

FV621 De Groot et al 2021
Immune camouflage: Relevance to vaccines and human immunology

Immune camouflage: Relevance to vaccines and human immunology

by Annie De Groot | Jan 13, 2020

De Groot et al. – 2014 – Immune camouflage Relevance to vaccines and human immunology
Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction

Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction

by Annie De Groot | Nov 12, 2019

Tregitope in T1D Nature Scientific Reports With Suppliment Nov 2019
« Older Entries

Recent Posts

  • From Kyoto, with Love
  • EpiVax Turns 25!
  • Happy Valentine’s Day! And don’t argue with Chatbots!
  • ISPRI in silico Toolkit in the Literature
  • Platform shoes, Bellbottoms and #CrueltyFreeFDA!

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562